Myriad takes genetic tests to UK, Ireland and Canada
This article was originally published in Clinica
Myriad Genetics has formed two agreements for its molecular diagnostic cancer tests - in the UK/Ireland and in Canada. Myriad says the two deals are part of its strategy to expand its molecular diagnostics business into "multiple foreign markets during 2000". Last month it signed an exclusive licensing agreement with Japanese company Falco biosystems.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.